Filtered By:
Condition: Heart Valve Disease
Education: Study
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 330 results found since Jan 2013.
Mitralign raises $10m
Mitralign, which is looking to commercialize its namesake mitral valve treatment and pursue regulatory nods for its Trialign tricuspid valve device, said it raised nearly $10 million.
The $9.8 million funding, of a hoped-for $30.2 million, came from 19 unnamed investors beginning last September, the Tewksbury, Mass.-based company said in a regulatory filing. Mitralign raised a $40 million Series E round in May 2016.
The Mitralign and Trialign devices are designed to use wire and catheters to implant polyester anchors within the annulus of the mitral and tricuspid valves. The anchors are then cinched together to reduce v...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Replacement Heart Valves Wall Street Beat Mitralign Inc. Source Type: news
Supra ‐annular structure assessment for self‐expanding transcatheter heart valve size selection in patients with bicuspid aortic valve
ConclusionsA supra‐annular structure based sizing strategy is feasible for TAVR in patients with bicuspid AS.
Source: Catheterization and Cardiovascular Interventions - February 5, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Xianbao Liu, Yuxin He, Qifeng Zhu, Feng Gao, Wei He, Lei Yu, Qijing Zhou, Minjian Kong, Jian'an Wang Tags: ORIGINAL STUDIES Source Type: research
LivaNova launches post-market study of bioprosthetic aortic heart valves
LivaNova (NSDQ:LIVN) announced today that the first patient has been enrolled in a post-market trial evaluating the overall incidence of reduced leaflet motion identified by CT imaging in patients receiving a bioprosthetic aortic heart valve.
Four-dimensional CT scans will be taken of the trial’s 230 participants at least 30 days after they stop anticoagulation or dual antiplatelet therapy, according to LivaNova. The study will also include one year of follow-up.
“Thrombus formation on valve leaflets has been shown to occur in some patients receiving prosthetic tissue valve replacement via transcatheter or ope...
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Imaging Wall Street Beat LivaNova Source Type: news
Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice
ConclusionsNOACs are increasingly used in German nursing homes, both for initial anticoagulation but also in VKA pre‐treated patients. Switching from VKA to NOAC was substantially influenced by aspects such as intended higher effectiveness and safety but probably also practicability due to less blood monitoring.
Source: British Journal of Clinical Pharmacology - January 11, 2018 Category: Drugs & Pharmacology Authors: Kathrin Jobski, Falk Hoffmann, Stefan Herget ‐Rosenthal, Michael Dörks Tags: PHARMACOEPIDEMIOLOGY Source Type: research
3 Reasons TAVR Will Continue to Prosper
The transcatheter aortic valve replacement (TAVR) market has already seen rapid growth, and today represents a $3 billion market globally. But the leading TAVR companies say the current technology and approved indications barely scratches the surface in terms of the true growth potential of the space.
Michael Mussallem, CEO of Edwards Lifesciences, told J.P. Morgan Healthcare Conference attendees on Monday that the global TAVR market is expected to exceed $5 billion by 2021, and that number does not include certain indications that are currently being explored, like treatment for patients with asymptomatic aortic stenosi...
Source: MDDI - January 9, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Cardiovascular Source Type: news
Transcatheter Aortic Valve Implantation in High-Risk/Inoperable Patients: Repositionable versus Non-Repositionable Self-Expanding Valve.
CONCLUSIONS: In comparison to last-generation CVS, the repositionable ERS is safe and effective in HRI patients. Similar rates of PM use were noted for each group. together with a favorable hemodynamic performance and fewer vascular complications.
PMID: 29302939 [PubMed - in process]
Source: Journal of Heart Valve Disease - January 7, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Long-Term Results of Aortic Root Surgery in Marfan Syndrome Patients: A Single-Center Experience.
CONCLUSIONS: The Bentall and David operations are both associated with satisfactory long-term results in MFS patients. The low rate of valve prosthesis-related complications suggested that the Bentall operation would continue to be a standard surgical treatment. The reimplantation technique, adopted for less-dilated aortas, provides satisfactory freedom from reoperation. Careful attention should be paid to the reimplantation technique in patients affected by a serious familiar genetic phenotype.
PMID: 29302938 [PubMed - in process]
Source: Journal of Heart Valve Disease - January 7, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience
Semin Thromb Hemost DOI: 10.1055/s-0037-1615261This is an observational study to investigate the efficacy and safety of nonvitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with bioprosthetic valves or prior surgical valve repair in clinical practice. A total of 122 patients (mean age: 74.1 ± 13.2; 54 females) with bioprosthetic heart valve or surgical valve repair and AF treated with NOACs were included in the analysis. The mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, prior Stroke or transient ischemic attack, Vascular disease) and...
Source: Seminars in Thrombosis and Hemostasis - January 5, 2018 Category: Hematology Authors: Russo, Vincenzo Attena, Emilio Mazzone, Carmine Esposito, Francesca Parisi, Valentina Bancone, Ciro Rago, Anna Nigro, Gerardo Sangiuolo, Raffaele D' Onofrio, Antonio Tags: Original Article Source Type: research
In-vitro hydrodynamic and acute clinical performance of a novel self-expanding THV in various surgical bioprostheses.
CONCLUSIONS: The NVT AllegraTM performed well for in-vitro ViV-TAVI analyses. Hereby, the AllegraTM combined the benefits of supra-annular self-expanding prostheses with regards to EOA and mean gradients with low amounts of regurgitation. Additionally, clinical implantation of the 23mm AllegraTM for the treatment of degenerated surgical bioprostheses was feasible and resulted in favorable hemodynamics.
PMID: 29260712 [PubMed - as supplied by publisher]
Source: EuroIntervention - December 22, 2017 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
Thirty-Day Outcomes in 100 Consecutive Patients Undergoing Transfemoral Aortic Valve Replacement With the Portico Valve on an All-Comer Basis.
CONCLUSIONS: Our immediate and 30-day post-TAVR results support favorable survival comparable to other studies, and significant clinical improvement with the Portico valve in non-selected patients in a real-world setting, with short-term complications being uncommon.
PMID: 29207365 [PubMed - in process]
Source: The Journal of Invasive Cardiology - December 6, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
TCT 2017: Medtronic touts results from 6-month Evolut Pro study
Medtronic (NYSE:MDT) today released six-month data from a study of its Evolut Pro transcatheter aortic valve replacement platform, touting low rates of paravalvular leaks and low rates of all-cause mortality and disabling stroke.
Data came from 60 patients in the trial who received the Evolut Pro valve, and follow previously released 30-day outcomes.
Results at six-months indicated trace or no paravalvular leaks in 88% of patients, with low rates of all-cause mortality and disabling stroke. No instances of coronary obstruction or valve thrombosis were reported and the permanent pacemaker implantation rate was 11.7%, Medt...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Catheters Clinical Trials Replacement Heart Valves Medtronic Source Type: news
Oral Anticoagulants in German nursing home residents – Drug use patterns and predictors for treatment choice
ConclusionsNOACs are increasingly used in German nursing homes, both for initial anticoagulation but also in VKA pre‐treated patients. Switching from VKA to NOAC was substantially influenced by aspects such as intended higher effectiveness and safety but probably also practicability due to less blood monitoring.
Source: British Journal of Clinical Pharmacology - November 1, 2017 Category: Drugs & Pharmacology Authors: Kathrin Jobski, Falk Hoffmann, Stefan Herget ‐Rosenthal, Michael Dörks Tags: PHARMACOEPIDEMIOLOGY Source Type: research
TCT 2017: Medtronic touts 1-year intermediate data for Evolut R TAVR
Medtronic (NYSE:MDT) is touting data from a pair of studies of intermediate-risk patients implanted with its Evolut R replacement heart valve, presented today at the Transcatheter Cardiovascular Therapeutics annual meeting in Denver.
Fridley, Minn.-based Medtronic presented results from its Surtavi trial and Evolut R Forward real-world study of its next-generation transcatheter aortic valve replacement today at TCT.
One-year data from Surtavi, comparing the Evolut R and CoreValve devices with open heart surgery, showed a 7.8% mortality rate for the TAVR arm, compared with 8.5% for the open surgery arm. A sub-group analysi...
Source: Mass Device - October 31, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Replacement Heart Valves Medtronic Source Type: news
Claret Medical raises $21m to support Sentinel system
Claret Medical has raised $21.2 million in a new round of equity financing, according to an SEC filing posted last week.
In a press release posted today, the company said that it raised $14.5 million in a Series C round led by Lightstone Ventures and joined by Easton Capital, HealthCor Partners, Incept and Sante Ventures.
Proceeds are slated to support market access program, next-gen R&D and expanding commercialization to support its Sentinel cerebral protection system.
The Sentinel embolic protection device is designed to trap blood clots and prevent stroke during heart valve replacement procedures, which Claret Medic...
Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Claret Medical Inc. Source Type: news
Multicenter Comparison of Novel Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves
Conclusions
Very high success rates were achieved for both valves, and the clinical and procedural results were comparable. Compared with S3, NEO was associated with less new pacemaker implantations and less elevated gradients, but with more paravalvular leakage.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 16, 2017 Category: Cardiology Authors: Husser, O., Kim, W.-K., Pellegrini, C., Holzamer, A., Walther, T., Mayr, P. N., Joner, M., Kasel, A. M., Trenkwalder, T., Michel, J., Rheude, T., Kastrati, A., Schunkert, H., Burgdorf, C., Hilker, M., Möllmann, H., Hengstenberg, C. Tags: Structural Source Type: research
